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Objectives: The results of many clinical trials demonstrate the benefit of long-
term antiplatelet therapy in reducing the risk of cardio- and cerebrovascular com-
plications. Both acetylsalicylic acid (ASA) and clopidogrel are effective, but have 
potentially serious side effects, and clopidogrel is more expensive than ASA. The 
purpose of the study is to evaluate the pharmacoeconomic acceptance of clopi-
dogrel versus ASA in patients with atherosclerotic vascular disease manifested 
as either recent ischaemic stroke, recent myocardial infarction, or symptomatic 
peripheral arterial disease to prevent non-fatal stroke and death rate according to 
the clinical trial CAPRIE from Ukrainian perspective. MethOds: Outcomes of the 
clinical study CAPRIE, modeling “decision tree” and analysis “cost-effectiveness” 
were used. Results: The results of the clinical trial CAPRIE study showed, that 
clopidogrel is more effective versus ASA for reducing the risk of nonfatal stroke: 
absolute risk reduction is -2.7%. Model “decision tree” was built using the probabili-
ties of events (nonfatal stroke and death) from the study CAPRIE. Direct costs were 
calculated taking into account the costs of antiplatelet therapy, of nonfatal stroke 
treatment (drugs, diagnosis, patient’s stay in hospital) and the cost of rehabilita-
tion after stroke. Indirect costs are not taken into account because the patients 
were of retirement age (62.5 years old). As a result of calculations it was found, 
that antiplatelet therapy with clopidogrel is more expensive and more effective (2 
additional lives saved per 1000 patients over 1.91 years) compared with ASA. Due 
to the threshold of society “willingness to pay” per 1 life saved, or 1 QALY, use of 
clopidogrel as antiplatelet agent in patients with cardiovascular disease is economi-
cally profitable for Ukraine. cOnclusiOns: The use of clopidogrel as an antiplatelet 
agent in patients with cardiovascular disease to prevent nonfatal stroke compared 
to the ASA is economically profitable for Ukraine.
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Objectives: Stroke and its associated disability costs the European Union an esti-
mated € 62 billion per year. Warfarin is the mainstay for stroke prevention in atrial 
fibrillation (AF), but many patients have absolute contraindications to this drug. The 
Watchman device for left atrial appendage closure (LAAC) received CE mark for stroke 
prevention in AF patients with contraindications to warfarin. This analysis sought to 
estimate the cost effectiveness of treating warfarin-ineligible AF patients with LAAC 
as compared to standard aspirin therapy. MethOds: A Markov model was developed 
comparing clinical outcomes and total costs between patients treated with LAAC or 
aspirin over 5 and 10 years based largely on clinical outcomes from the Aspirin and 
Plavix Registry (ASAP) and ACTIVE trials. Clinical events included ischemic stroke, 
TIA, systemic embolism, bleeding, and acute myocardial infarction as well as proce-
dure-related events. Germany was chosen as the country of analysis because of its 
unique DRG for the LAAC procedure. Acute costs were taken from German DRGs and 
long-term disability costs were taken from the Berlin Acute Stroke Study. Sensitivity 
analysis was performed on clinical and cost inputs; the model was most sensitive 
to changes in the rate of ischemic stroke. Results: LAAC demonstrated a benefit 
in terms of ischemic strokes and mortality avoided. The cost per ischemic stroke 
avoided was € 91,020 and € 24,722 at 5 and 10 years, respectively. The cost per life year 
gained for LAAC versus aspirin was € 22,694 at 5 years and decreased to € 5,859 at 
10 years. cOnclusiOns: LAAC is a cost-effective alternative to aspirin therapy in 
patients with contraindications to warfarin. Cost offsets achieved with LAAC become 
considerably more pronounced over time. This analysis highlights the importance of 
considering the lifetime costs of stroke prevention in AF, especially as the probability 
of both stroke and bleeding increases with patient age.
PCV80
Cost-effeCtiVeness of riVaroxaban in the PreVention of stroke in 
non-ValVular atrial fibrillation Patients in italy
Capri S.1, Veneziano M.2, Ricciardi W.G.2, D’Ausilio A.3, Pedone M.P.4, Bianchi C.4
1Institute of Economics, Castellanza, Italy, 2Catholic University of Sacred Heart, Rome, Italy, 
3Creativ Ceutical, Luxembourg, Luxembourg, 4Bayer Pharma, Milano, Italy
Objectives: To perform a cost-effectiveness analysis of rivaroxaban (once-daily) in 
the prevention of stroke and systemic embolism of patients with non-valvular atrial 
fibrillation (NVAF) and in patients sub-groups from the perspective of the Italian 
health care system (SSN). MethOds: A Markov model was developed with a life-
time timeframe where a hypothetic NVAF patients’ cohort is treated with Vitamin-K 
antagonists (VKAs), antiplatelet drugs (ASA) or no therapy. Patients remain stable 
or progress towards other health states (ischemic or hemorrhagic stroke, myocar-
dial infarction and bleedings) until death. The base case compares rivaroxaban 
with VKAs. In subgroup analyses, rivaroxaban is compared with patients at highest 
unmet medical need: 1. VKA patients with poor INR control, 2. patients under ASA 
or 3. not treated. Clinical data were derived from ROCKET-AF trial or a network 
meta-analysis. Utility data were retrieved from published literature. Health care 
resources consumption was valued using average regional tariffs in Italy. Since 
rivaroxaban price is not officially published, the price of the first novel oral antico-
agulant approved in this indication in Italy was considered. Model outcomes are 
expressed in terms of incremental cost per quality adjusted life year (QALY) gained 
(ICER). Univariate and probabilistic sensitivity analyses were performed Results: 
In the base case, rivaroxaban showed to be cost-effective compared to VKA with an 
VKA-unsuitable, respectively) formed the basis of the analysis. Clinical events 
(ischemic strokes, hemorrhagic strokes, intracranial hemorrhages, other major 
bleeds, clinically relevant non-major bleeds, myocardial infarctions and car-
diovascular hospitalizations) were modeled over a lifetime horizon based on 
the clinical efficacy of each comparator, as reported by two phase-III clini-
cal trials (ARISTOTLE and AVERROES). Resource use with regards to patient 
monitoring was elicited via an experts’ panel (cardiologists & internists). 
Cost calculations reflect the local clinical setting, and followed a third-party 
payer perspective (Euros, year 2013, discounted at 3%). Results: Apixaban 
was projected to reduce the occurrence of clinical events and increase quality 
adjusted life expectancy compared to warfarin and aspirin (an incremental 
increase of 0.225 and 0.274 QALYs per patient, respectively). Taking into account 
costs of medications, treatment and management of events, the incremental 
cost-effectiveness ratio for apixaban versus warfarin and aspirin was esti-
mated at 12,154.6 € /QALY and 5,980.6 € /QALY gained, respectively. Extensive 
sensitivity analyses indicated that results were robust over a wide range of 
inputs. cOnclusiOns: Based on the results of this analysis, apixaban can 
be a cost-effective alternative to warfarin and aspirin for the management of 
VKA-suitable and VKA-unsuitable patients with NVAF, respectively, in Greece.
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Objectives: Intravascular ultra-sound (IVUS) allows physicians to generate a supe-
rior image of coronary arteries during percutaneous coronary interventions (PCI), 
providing a tomographic, 360-degree view of the arterial wall from the inside, which 
allows a more accurate and complete assessment than is possible with angiography. 
The purpose of this study was to understand the cost-effectiveness of IVUS com-
pared with traditional angiography techniques in drug-eluting stent (DES) implanta-
tion, from the perspective of the Italian health system. MethOds: A Markov model 
was developed to extrapolate the comparative costs and outcomes of a theoretical 
population of 1000 patients undergoing DES implantation with traditional angiogra-
phy alone, or in conjunction with IVUS. The model assesses cardiac events, including 
revascularisations and myocardial infarctions from a health system perspective. 
Outcomes with and without IVUS were based on a meta-analysis by Zhang et al 
(2013). Because of limited clinical evidence to inform the long-term outcomes of 
IVUS compared with angiography, the model either assumes the benefit of IVUS 
is conferred only in the first year of treatment, or that the benefit is maintained 
permanently. Results: Using IVUS during PCI cost an average of € 542 per patient, 
and yields an additional 0.022 quality adjusted life years (QALYs) per patient. In a 
population of 1,000 patients, IVUS led to a reduction of 6.7 revascularisations and 
5.9 less myocardial infarctions (MI) over the lifetime of a patient. When the revas-
cularisation and MI benefit of IVUS is assumed to extend for the patient’s lifetime, 
angiography with IVUS costs € 38 per patient and yields an additional 0.09 QALYs 
over a patient’s lifetime; avoiding 13.4 MIs and 12.3 revascularisations per 1,000 
patients. cOnclusiOns: IVUS appears to be a cost-effective addition to traditional 
angiography in DES placement in Italy, with the increased upfront cost of IVUS offset 
by reduced cardiac events in IVUS-treated patients over time.
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Objectives: Apixaban, dabigatran (150 mg BID and 110 mg BID) and rivaroxaban 
are three novel oral anticoagulants (NOACs) currently approved for stroke preven-
tion and systemic embolism in non-valvular atrial fibrillation (NVAF) patients. 
The objective of this analysis was to assess the cost-effectiveness (CE) of apixa-
ban against other NOACs for the prevention of stroke in patients with NVAF in 
Greece. MethOds: A Markov model that evaluated clinical events, quality adjusted 
life expectancy and costs for patients treated with apixaban or other NOACs formed 
the basis of the analysis. Clinical events (ischemic strokes, hemorrhagic strokes, 
intracranial hemorrhages, other major bleeds, clinically relevant non-major bleeds, 
myocardial infarctions and cardiovascular hospitalizations) were modeled for a 
lifetime horizon. Due to lack of head-to-head comparisons, efficacy and safety data 
was derived from an indirect treatment comparison (ITC). The key pivotal trials, 
ARISTOTLE, ROCKET-AF and RE-LY, all included warfarin as a comparator therefore 
allowing for an ITC. Resource use with regards to patient monitoring was elic-
ited via a panel of experts (cardiologists & internists). Cost calculations reflect the 
local clinical setting and followed a third-party payer perspective (Euros, year 2013, 
discounted at 3%). Results: Apixaban was projected to reduce the occurrence of 
clinical events and increase quality-adjusted life expectancy and costs of treatment 
compared to other NOACs. Taking into account costs of medications, treatment 
and management of events, the incremental cost-effectiveness ratios for apixaban 
5 mg BID versus dabigatran 150 mg BID, dabigatran 110 mg BID and rivaroxaban 
20 mg QD were estimated at 15,403€ /QALY, 4,955€ /QALY and 10,130 € /QALY gained, 
respectively. Extensive sensitivity analyses indicated that results were robust over a 
wide range of inputs. cOnclusiOns: Based on the results of this analysis, apixaban 
can be a cost-effective alternative to other NOACs, for the prevention of strokes in 
patients with NVAF in Greece.
